Compare SBR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBR | ABCL |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 3.5B |
| IPO Year | N/A | 2020 |
| Metric | SBR | ABCL |
|---|---|---|
| Price | $75.10 | $11.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 23.4K | ★ 5.2M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.41% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | $12.77 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $65.31 | $2.75 |
| 52 Week High | $84.39 | $12.58 |
| Indicator | SBR | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 56.96 |
| Support Level | $72.58 | $10.44 |
| Resistance Level | $76.59 | $12.58 |
| Average True Range (ATR) | 1.46 | 0.65 |
| MACD | -0.05 | -0.27 |
| Stochastic Oscillator | 28.37 | 37.61 |
Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.